GU Cast in Lugano this week for #APCCC24 @APCCC_Lugano and will bring you all the highlights! Check out our three fantastic podcasts from last #APCCC22 for a favour of our favourite prostate cancer meeting @declangmurphy @RenuEapen @Uromigos @OncoAlert youtu.be/oYZSGyN9BlM?si=ZdWw…

The dynamic field of advanced #ProstateCancer is ever-evolving, and so is our quest for consensus. Our last week's Twitter poll of an #APCCC22 consensus question on managing high-risk prostate cancer with 1-3 bone lesions post-PSMA PET revealed diverse expert opinions – a reflection of the intricate nature of oncology. 📊 Poll Results: 1️⃣ Conventional imaging: 37.8% 2️⃣ Biopsy if feasible: 14.9% 3️⃣ No further metastases investigations: 41.9% 4️⃣ Abstain/unqualified to answer: 5.4% These insights push us to delve deeper, discuss broader, and engage further. Your expertise is invaluable as we gear up for #APCCC24. Let's unravel these complexities together. 🤝 Join the conversation and help shape the future of cancer management. Register for APCCC 2024: apccc.org/ #OncologyResearch #MedicalConference #CancerCare

Reflecting on #APCCC22's consensus questions, we're gearing up for more engaging discussions at #APCCC24! 🤔 💡 Your insights are crucial as we navigate complex advanced prostate cancer management topics. Join us in Lugano, where every voice advances our understanding and patient care. 🌍 Free virtual access for low and lower-middle income countries & special rates for nurses, charities, and students. Early bird ends Feb 22! 🔗 Register now: apccc.org/ #ProstateCancer #Oncology #GlobalHealth @Silke_Gillessen @AOmlin @OncoAlert

#APCCC22 Consensus Questions: At what confirmed PSA level do you recommend imaging for asymptomatic patients with rising PSA after radical (definitive) radiation therapy with an interval to biochemical failure <18 months OR biopsy ISUP grade group 4–5 (EAU high-risk)? 1. Before PSA reaches 2ng/mL above nadir 2. ≥2 ng/mL above nadir 3. ≥2 ng/mL above nadir with PSA doubling time <12 months 3. Abstain/unqualified to answer (including I do not recommend imaging at all in this setting) #prostatecancer #APCCC24

🌟 Explore the depth of the #APCCC22 Report on advanced prostate cancer management! >>Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022<< 🔬 Focus Areas: ・Metastatic hormone-sensitive prostate cancer (mHSPC) ・Non-metastatic & metastatic castration-resistant prostate cancer (nmCRPC & mCRPC) ・Oligometastatic progression ・and more 👨‍🔬👩‍🔬 Essential for #Oncology and #Urology professionals with cutting-edge insights for clinical decision-making. 🧠 Discover consensus in treatment strategies and therapeutic approaches. Join top experts in tackling the complexities of advanced prostate cancer care. ✅ A vital resource for healthcare professionals striving to enhance cancer care and patient outcomes. 📥 Access the comprehensive guide here: apccc.org/home/publications #ProstateCancer #CancerTreatment #MedicalResearch #HealthcareInnovation #APCCC24

🤔49. In the majority of patients with a PSA rise after radical prostatectomy ( /- salvage RT of the prostate bed) and 1-3 positive lymph nodes in the pelvis alone on PSMA PET, what is your treatment recommendation? 1. Loco-regional treatment alone 2. Systemic therapy alone 3. Loco-regional treatment plus systemic therapy 4. Abstain/unqualified to answer on #APCCC22 #APCCC24 #ProstateCancer

Discover the consensus regarding the impact of next-generation imaging in localised #prostatecancer from #APCCC22. What do the experts say? Find out in our comprehensive report. Download now to stay ahead in advanced PCa management. 👉 apccc.org/ #APCCC24

#APCCC22 Qn. 42. For the majority of patients with rising PSA after radical prostatectomy and PSA-DT <1 yr or pathological ISUP grade group 4–5 (EAU high risk), at what confirmed rising PSA level do you recommend PSMA PET imaging? #APCCC24 #Consensus #Prostateancer

Advance your knowledge of advanced prostate cancer management! The #APCCC22 Consensus Report Part II explores seven controversial areas in the field. Get your copy and join us in revolutionising patient care: apccc.org/home/publications/ #APCCC24 #ProstateCancer #Oncology

Keep yourself updated with our latest consensus in advanced #prostatecancer management! The #APCCC22 Report brings together the knowledge of 117 experts in the field. Don't miss out; get your copy today! apccc.org/home/publications/ #CancerResearch #AdvancedProstateCancer #APCCC24

Consensus in the management of advanced prostate cancer? Find out in the #APCCC22 Consensus Report Part II, crafted by a panel of 117 expert physicians and scientists. Get the insights you need right here: apccc.org/home/publications/ #ProstateCancer #CancerResearch #APCCC24

Have you checked out the APCCC 2022 Consensus Report yet? 📖 Compiled by 117 global experts, it offers valuable insights into seven key areas of advanced prostate cancer. Expand your knowledge today! apccc.org/home/publications/ #APCCC22 #ProstateCancer #Oncology #APCCC24

Consensus in the management of advanced prostate cancer? Find out in the #APCCC22 Consensus Report Part II, crafted by a panel of 117 expert physicians and scientists. Get the insights you need right here: apccc.org/home/publications/ #ProstateCancer #CancerResearch #APCCC24

Keep yourself updated with our latest consensus in advanced #prostatecancer management! The #APCCC22 Report brings together the knowledge of 117 experts in the field. Don't miss out; get your copy today! apccc.org/home/publications/ #CancerResearch #AdvancedProstateCancer #APCCC24

Advance your knowledge of advanced prostate cancer management! The #APCCC22 Consensus Report Part II explores seven controversial areas in the field. Get your copy and join us in revolutionising patient care: apccc.org/home/publications/ #APCCC24 #ProstateCancer #Oncology

Have you checked out the APCCC 2022 Consensus Report yet? 📖 Compiled by 117 global experts, it offers valuable insights into seven key areas of advanced prostate cancer. Expand your knowledge today! apccc.org/home/publications/ #APCCC22 #ProstateCancer #Oncology #APCCC24

Access the #APCCC22 Report of the Advanced Prostate Cancer Consensus Conference 2022: 👉 apccc.org/apccc-2022/publica…

Qn6: In the majority of PTS w/ clinically localised #prostatecancer PSMA positive, w/ metastases consistent findings in the bone on the CT part of an upfront PSMA PET, do you recommend additional imaging (e.g. MRI, bone scintigraphy)? #APCCC24 #APCCC22 #ConsensusQuestion

Localised Prostate Cancer: Impact of Next Generation Imaging: QN 13. What do you recommend in the majority of patients with clinically localised #prostatecancer with M0 on conventional imaging but 1-3 PSMA positive bone lesions? #APCCC24 #APCCC22 #ConsensusQuestion

We're excited to be joined today by close to 30 clinical experts from 14 countries to review & test 5 key themes from St Gallen #APCCC22 from an APAC perspective. Looking forward to fantastic @ANZUPTrials #ProstateCancer consensus meeting @Prof_IanD @declangmurphy @EdChiongUROonc